Christine R. Bryke

Medical Genetics

330 Brookline Ave
Beth Israel Deaconess Medical Center
Boston, MA 02215

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Cytogenetic and Molecular Characterization of IDH-Wildtype Glioblastomas and Grade 4 IDH-Mutant Astrocytomas with Unusual Histology.

Cytogenetic and Molecular Characterization of IDH-Wildtype Glioblastomas and Grade 4 IDH-Mutant Astrocytomas with Unusual Histology.

Journal: Journal of neuropathology and experimental neurology

Published: October 19, 2022

JAK2 Mutations Are Rare and Diverse in Myelodysplastic Syndromes: Case Series and Review of the Literature.

JAK2 Mutations Are Rare and Diverse in Myelodysplastic Syndromes: Case Series and Review of the Literature.

Journal: Hematology reports

Published: October 04, 2022

Cytogenetically cryptic PML::RARA fusion in acute promyelocytic leukemia: Testing strategies in the modern era.

Cytogenetically cryptic PML::RARA fusion in acute promyelocytic leukemia: Testing strategies in the modern era.

Journal: Leukemia research reports

Published: February 11, 2022

Multiple Whole Chromosomal Gains Define Angiomatous Meningiomas and Are Absent From the Tumor Vasculature.

Multiple Whole Chromosomal Gains Define Angiomatous Meningiomas and Are Absent From the Tumor Vasculature.

Journal: Journal of neuropathology and experimental neurology

Published: January 27, 2020

A high-grade glioma with SOS1 amplification.

A high-grade glioma with SOS1 amplification.

Journal: Clinical neuropathology

Published: December 17, 2019

Papillary haemangioma in the spinal canal of a patient with a germline 12p microdeletion.

Papillary haemangioma in the spinal canal of a patient with a germline 12p microdeletion.

Journal: Histopathology

Published: March 19, 2019

Characteristics of myeloproliferative neoplasms in patients exposed to ionizing radiation following the Chernobyl nuclear accident.

Characteristics of myeloproliferative neoplasms in patients exposed to ionizing radiation following the Chernobyl nuclear accident.

Journal: American journal of hematology

Published: September 24, 2018

EBV-positive, HHV8-negative large B-cell lymphoma with an unusual germinotropic growth pattern in an immunocompetent patient.

EBV-positive, HHV8-negative large B-cell lymphoma with an unusual germinotropic growth pattern in an immunocompetent patient.

Journal: Clinical case reports

Published: March 21, 2018

Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms.

Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms.

Journal: Cancer genetics

Published: March 11, 2018

Assessing copy number abnormalities and copy-neutral loss-of-heterozygosity across the genome as best practice in diagnostic evaluation of acute myeloid leukemia: An evidence-based review from the cancer genomics consortium (CGC) myeloid neoplasms working group.

Assessing copy number abnormalities and copy-neutral loss-of-heterozygosity across the genome as best practice in diagnostic evaluation of acute myeloid leukemia: An evidence-based review from the cancer genomics consortium (CGC) myeloid neoplasms working group.

Journal: Cancer genetics

Published: March 05, 2018

Possible reactivation of chromosomally integrated human herpesvirus 6 after treatment with histone deacetylase inhibitor.

Possible reactivation of chromosomally integrated human herpesvirus 6 after treatment with histone deacetylase inhibitor.

Journal: Blood advances

Published: January 09, 2018

Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E.

Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E.

Journal: Oncotarget

Published: July 14, 2017

Showing 1-12 of 15

Last Updated: 09/26/2026